Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics.[1] Bristol Myers Squibb acquired the company in January 2024.[2]
| Company type | Subsidiary |
|---|---|
| |
| Industry | Oncology |
| Founded | 1995 |
| Headquarters | San Diego, California, U.S. |
Key people | David Meek |
Number of employees | 600 (2022) |
| Parent | Bristol Myers Squibb |
| Website | mirati |
History edit
Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[3] The inhibition to the mutation has shown to shrink the size of its tumors.[4] The company is based in San Diego, California.[5] The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the Nasdaq[6] under the ticker symbol MRTX.[7] It joined the exchange in 2013.[8]
In October 2023, Bristol Myers Squibb agreed to acquire the company in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment.[9] The acquisition was completed in January 2024.[2]
Drug candidates edit
The company’s leading drug candidates are sitravatinib and adagrasib.[5] Mirati also has a preclinical candidate against the G12D mutation.[10]
Management edit
The company’s CEO and President is David Meek.[11]
References edit
- ^ Flanagan C (25 October 2020). "Hedge Fund Pick Mirati Rallies to Record After Drug Results". BloombergQuint.
- ^ a b "Bristol Myers Squibb concludes Mirati acquisition for $5.8bn". Pharmaceutical Technology. Verdict Media. 24 January 2024.
- ^ Ingham E (1 January 2021). "Mirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big Deal (NASDAQ:MRTX)". Seeking Alpha.
- ^ Garage JL (October 28, 2019). "Mirati drug shrinks tumors in some cancer patients in early-stage trial". CNBC.
- ^ a b Tran H (31 December 2020). "Mirati Therapeutics: A Gift That Keeps On Giving (NASDAQ:MRTX)". Seeking Alpha.
- ^ Speights K (26 October 2020). "Why Mirati Therapeutics Stock Is Taking Off Today". The Motley Fool.
- ^ BNK Invest (29 March 2021). "RSI Alert: Mirati Therapeutics (MRTX) Now Oversold". NASDAQ.
- ^ Whitlock J (7 July 2021). "Mirati Therapeutics Raises $234.3M in Public Stock Offering". San Diego Business Journal.
- ^ Condie, Stuart (8 October 2023). "Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion". The Wall Street Journal.
- ^ Martz L (26 October 2019). "How a KRAS program transformed Mirati's story". BioCentury.
- ^ Mirati (20 September 2021). "Mirati Therapeutics Appoints David Meek as Chief Executive Officer".
External links edit
- Official website
- Historical business data for Mirati Therapeutics, Inc.:
- SEC filings